nach oben

Erschienen in:

11.11.2017 | Fortbildung

GKV-Verordnung von Cannabis — Teil 2: Anwendungspraxis

Bei Cannabis auf BTM-Rezept Haftungs- und Regressrisiko beachten

verfasst von: Prof. Dr. med. Wolfgang Freund, Ludwig Laub, Prof. Dr. med. Ulrich W. Preuss

Erschienen in: NeuroTransmitter | Ausgabe 11/2017

Einloggen, um Zugang zu erhalten

Zusammenfassung

Im ersten Teil dieses Artikels zur GKV-Verordnung von Cannabisprodukten wurden die derzeitige Evidenz zur Wirkung von Cannabis und relevante Aspekte zur Pharmakologie zusammengefasst. Dieser zweite Teil behandelt die praktische Anwendung von Cannabisprodukten und die rechtlichen Aspekte von BTM-Status über Fahreignung, Produkthaftung bis zur Patientenaufklärung und Regressgefahr.

Gesetz zur Änderung betäubungsmittelrechtlicher und anderer Vorschriften (2017). Bundesgesetzblatt, vol Teil I Nr. 11, 09.03.2017.

Aizpurua-Olaizola O, Elezgarai I, Rico-Barrio I, Zarandona I, Etxebarria N, Usobiaga A (2017) Targeting the endocannabinoid system: future therapeutic strategies. Drug discovery today 22(1):105–110. doi:10.1016/j.drudis.2016.08.005CrossRefPubMed

Chen J, Varga A, Selvarajah S, Jenes A, Dienes B, Sousa-Valente J, Kulik A, Veress G, Brain SD, Baker D, Urban L, Mackie K, Nagy I (2016) Spatial Distribution of the Cannabinoid Type 1 and Capsaicin Receptors May Contribute to the Complexity of Their Crosstalk. Scientific reports 6:33307. doi:10.1038/srep33307

Veress G, Meszar Z, Muszil D, Avelino A, Matesz K, Mackie K, Nagy I (2013) Characterisation of cannabinoid 1 receptor expression in the perikarya, and peripheral and spinal processes of primary sensory neurons. Brain structure & function 218(3):733–750. doi:10.1007/s00429-012-0425-2CrossRef

Tan Q, Chen Q, Feng Z, Shi X, Tang J, Tao Y, Jiang B, Tan L, Feng H, Zhu G, Yang Y, Chen Z (2017) Cannabinoid receptor 2 activation restricts fibrosis and alleviates hydrocephalus after intraventricular hemorrhage. Brain research 1654 (Pt A):24-33. doi:10.1016/j.brainres.2016.10.016

Inc. A (2017) Marinol. AbbVie. http://www.marinol.com/. Accessed 5.July2017 2017

Pertwee RG (2008) The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. British journal of pharmacology 153(2):199–215. doi:10.1038/sj.bjp.0707442CrossRefPubMed

Bridgeman MB, Abazia DT (2017) Medicinal Cannabis: History, Pharmacology, And Implications for the Acute Care Setting. P & T: a peer-reviewed journal for formulary management 42(3):180–188

Pertwee RG (2004) The pharmacology and therapeutic potential of cannabidiol.. In: Di Marzo V (ed) Cannabinoids. Kluwer Academic/ Plenum Publishers, New York, pp 32-83

10.

Fasinu PS, Phillips S, ElSohly MA, Walker LA (2016) Current Status and Prospects for Cannabidiol Preparations as New Therapeutic Agents. Pharmacotherapy 36(7):781–796. doi:10.1002/phar.1780CrossRefPubMed

11.

Havemann-Reinecke U, Hoch E, Preuss UW, Kiefer F, Batra A, Gerlinger G, Hauth I (2017) [On the legalization debate of non-medical cannabis consumption: Position paper of the German Association for Psychiatry, Psychotherapy and Psychosomatics]. Der Nervenarzt 88(3):291–298. doi:10.1007/s00115-016-0248-0CrossRefPubMed

12.

Elzinga S, Fischedick J, Podkolinski R, Raber JC (2015) Cannabinoids and Terpenes as Chemotaxonomic Markers in Cannabis. Natural Products Chemistry & Research 3(4):1–9. doi:10.4172/2329-6836.1000181

13.

Bussik D, Eckert-Lill C (2017) Cannabis als Medizin: Was kommt auf die Apotheken zu? Pharmazeutische Zeitung online 2017 (08)

14.

Müller-Vahl K, Grotenhermen F (2017) Medizinisches Cannabis: Die wichtigsten Änderungen. Deutsches Arzteblatt international 114(8):352–356

15.

Deutscher_Arzneimittel_Codex (2017) Ölige Dronabinol-Tropfen 25 mg/ml (NRF 22.8.). http://dacnrf.pharmazeutische-zeitung.de/index.php?id=aerzterezepturenfinderdetail&uid=495. Accessed 25.Juli 2017 2017

16.

Deutscher_Arzneimittel_Codex (2017) Ölige Cannabidiol-Lösung 50 mg/ml (NRF 22.10.). http://dacnrf.pharmazeutische-zeitung.de/index.php?id=aerzterezepturenfinderdetail&uid=3018. Accessed 25.Juli 2017 2017

17.

Deutscher_Arzneimittel_Codex (2017) Ölige Cannabisölharz-Lösung 25 mg/ml Dronabinol (NRF 22.11.) http://http://dacnrf.pharmazeutische-zeitung.de/index.php?id=aerzterezepturenfinderdetail&uid=3422. Accessed 25.Juli 2017 2017

18.

Almirall (2015) Sativex Spray zur Anwendung in der Mundhöhle - Fachinformation. https://http://www.almirallmed.de/documents/10327/18203/Sativex_Spray_zur_Anwendung_in_der_Mundhoehle_Fachinformation.pdf/be19eca4-d8be-4493-93fe-355d0bdfe1e7. Accessed 5.July2017 2017

19.

AOP_Orphan_Pharmaceuticals (2016) Canemes Fachinformation. Rote Liste Fachinfo Service. Rote Liste Fachinfo Service, Frankfurt

20.

Bundesinstitut_für_Arzneimittel_und_Medizinprodukte (2017) Cannabis als Medizin: Bundesinstitut für Arzneimittel und Medizinprodukte richtet Cannabisagentur für künftigen Cannabisanbau in Deutschland ein. BfArM. http://www.bfarm.de/SharedDocs/Pressemitteilungen/DE/2017/pm7-2017.html. Accessed 5.July2017 2017

21.

Arzneimittelkommission_der_deutschen_Ärzteschaft (2015) Cannabinoide in der Medizin. Arzneimittelkommission_der_deutschen_Ärzteschaft. Arzneimittelkommission_der_deutschen_Ärzteschaft, Berlin

22.

National Academies of Sciences E, Medicine (2017) The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research. The National Academies Press, Washington, DC. doi:doi:10.17226/24625

23.

Frank B, Serpell MG, Hughes J, Matthews JN, Kapur D (2008) Comparison of analgesic effects and patient tolerability of nabilone and dihydrocodeine for chronic neuropathic pain: randomised, crossover, double blind study. BMJ (Clinical research ed 336(7637):199–201. doi:10.1136/bmj.39429.619653.80CrossRefPubMedPubMedCentral

24.

Narang S, Gibson D, Wasan AD, Ross EL, Michna E, Nedeljkovic SS, Jamison RN (2008) Efficacy of dronabinol as an adjuvant treatment for chronic pain patients on opioid therapy. J Pain 9(3):254–264. doi:10.1016/j.jpain.2007.10.018CrossRefPubMed

25.

Portenoy RK, Ganae-Motan ED, Allende S, Yanagihara R, Shaiova L, Weinstein S, McQuade R, Wright S, Fallon MT (2012) Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial. J Pain 13(5):438–449. doi:10.1016/j.jpain.2012.01.003CrossRefPubMed

26.

Rog DJ, Nurmikko TJ, Friede T, Young CA (2005) Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology 65(6):812–819. doi:10.1212/01.wnl.0000176753.45410.8bCrossRefPubMed

27.

Wade DT, Makela P, Robson P, House H, Bateman C (2004) Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Multiple sclerosis (Houndmills, Basingstoke, England) 10(4):434–441. doi:10.1191/1352458504ms1082oaCrossRef

28.

Whiting PF, Wolff RF, Deshpande S, Di Nisio M, Duffy S, Hernandez AV, Keurentjes JC, Lang S, Misso K, Ryder S, Schmidlkofer S, Westwood M, Kleijnen J (2015) Cannabinoids for Medical Use: A Systematic Review and Meta-analysis. JAMA 313(24):2456–2473. doi:10.1001/jama.2015.6358CrossRefPubMed

29.

McLoughlin BC, Pushpa-Rajah JA, Gillies D, Rathbone J, Variend H, Kalakouti E, Kyprianou K (2014) Cannabis and schizophrenia. Cochrane Database Syst Rev (10):CD004837. doi:10.1002/14651858.CD004837.pub3

30.

Leweke FM, Piomelli D, Pahlisch F, Muhl D, Gerth CW, Hoyer C, Klosterkotter J, Hellmich M, Koethe D (2012) Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Translational psychiatry 2:e94. doi:10.1038/tp.2012.15CrossRefPubMedPubMedCentral

31.

Jetly R, Heber A, Fraser G, Boisvert D (2015) The efficacy of nabilone, a synthetic cannabinoid, in the treatment of PTSD-associated nightmares: A preliminary randomized, double-blind, placebo-controlled cross-over design study. Psychoneuroendocrinology 51:585–588. doi:10.1016/j.psyneuen.2014.11.002CrossRefPubMed

32.

Fitzcharles MA, Baerwald C, Ablin J, Hauser W (2016) Efficacy, tolerability and safety of cannabinoids in chronic pain associated with rheumatic diseases (fibromyalgia syndrome, back pain, osteoarthritis, rheumatoid arthritis): A systematic review of randomized controlled trials. Schmerz (Berlin, Germany) 30(1):47–61. doi:10.1007/s00482-015-0084-3CrossRef

33.

Light M, Orens A, Lewandowski B, Pickton T (2014) Market size and demand for marijuana in Colorado. State of Colorado. http://www.colorado.gov/pacific/sites/default/files/Market%20Size%20and%20Demand%20Study,%20July%209,%202014%5B1%5D.pdf. Accessed 25.07.2017 2017

34.

Ilgen MA, Bohnert K, Kleinberg F, Jannausch M, Bohnert AS, Walton M, Blow FC (2013) Characteristics of adults seeking medical marijuana certification. Drug and alcohol dependence 132(3):654–659. doi:10.1016/j.drugalcdep.2013.04.019CrossRefPubMed

35.

Bradford AC, Bradford WD (2016) Medical Marijuana Laws Reduce Prescription Medication Use In Medicare Part D. Health affairs 35(7):1230–1236. doi:10.1377/hlthaff.2015.1661CrossRefPubMed

36.

Abrams DI, Jay CA, Shade SB, Vizoso H, Reda H, Press S, Kelly ME, Rowbotham MC, Petersen KL (2007) Cannabis in painful HIV-associated sensory neuropathy: a randomized placebo-controlled trial. Neurology 68(7):515–521. doi:10.1212/01.wnl.0000253187.66183.9cCrossRefPubMed

37.

Andreae MH, Carter GM, Shaparin N, Suslov K, Ellis RJ, Ware MA, Abrams DI, Prasad H, Wilsey B, Indyk D, Johnson M, Sacks HS (2015) Inhaled Cannabis for Chronic Neuropathic Pain: A Meta-analysis of Individual Patient Data. J Pain 16(12):1221–1232. doi:10.1016/j.jpain.2015.07.009CrossRefPubMedPubMedCentral

38.

Snedecor SJ, Sudharshan L, Cappelleri JC, Sadosky A, Desai P, Jalundhwala YJ, Botteman M (2013) Systematic review and comparison of pharmacologic therapies for neuropathic pain associated with spinal cord injury. Journal of pain research 6:539–547. doi:10.2147/JPR.S45966CrossRefPubMedPubMedCentral

39.

Richards BL, Whittle SL, van der Heijde DM, Buchbinder R (2012) Efficacy and safety of neuromodulators in inflammatory arthritis: a Cochrane systematic review. The Journal of rheumatology Supplement 90:28–33. doi:10.3899/jrheum.120339CrossRefPubMed

40.

Lynch ME, Campbell F (2011) Cannabinoids for treatment of chronic non-cancer pain; a systematic review of randomized trials. British journal of clinical pharmacology 72(5):735–744. doi:10.1111/j.1365-2125.2011.03970.xCrossRefPubMedPubMedCentral

41.

Koppel BS, Brust JC, Fife T, Bronstein J, Youssof S, Gronseth G, Gloss D (2014) Systematic review: efficacy and safety of medical marijuana in selected neurologic disorders: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology 82 (17):1556–1563. doi:10.1212/WNL.0000000000000363CrossRefPubMedPubMedCentral

42.

Ashworth B (1964) Preliminary Trial of Carisoprodol in Multiple Sclerosis. The Practitioner 192:540–542PubMed

43.

Pandyan AD, Johnson GR, Price CI, Curless RH, Barnes MP, Rodgers H (1999) A review of the properties and limitations of the Ashworth and modified Ashworth Scales as measures of spasticity. Clinical rehabilitation 13(5):373–383. doi:10.1191/026921599677595404CrossRefPubMed

44.

Wade DT, Collin C, Stott C, Duncombe P (2010) Meta-analysis of the efficacy and safety of Sativex (nabiximols), on spasticity in people with multiple sclerosis. Multiple sclerosis (Houndmills, Basingstoke, England) 16(6):707–714. doi:10.1177/1352458510367462CrossRef

45.

Carroll CB, Bain PG, Teare L, Liu X, Joint C, Wroath C, Parkin SG, Fox P, Wright D, Hobart J, Zajicek JP (2004) Cannabis for dyskinesia in Parkinson disease: a randomized double-blind crossover study. Neurology 63(7):1245–1250CrossRefPubMed

46.

Sieradzan KA, Fox SH, Hill M, Dick JP, Crossman AR, Brotchie JM (2001) Cannabinoids reduce levodopa-induced dyskinesia in Parkinson’s disease: a pilot study. Neurology 57(11):2108–2111CrossRefPubMed

47.

Chagas MH, Zuardi AW, Tumas V, Pena-Pereira MA, Sobreira ET, Bergamaschi MM, dos Santos AC, Teixeira AL, Hallak JE, Crippa JA (2014) Effects of cannabidiol in the treatment of patients with Parkinson’s disease: an exploratory double-blind trial. J Psychopharmacol 28(11):1088–1098. doi:10.1177/0269881114550355CrossRefPubMed

48.

Lotan I, Treves TA, Roditi Y, Djaldetti R (2014) Cannabis (medical marijuana) treatment for motor and non-motor symptoms of Parkinson disease: an open-label observational study. Clinical neuropharmacology 37 (2):41–44. doi:10.1097/WNF.0000000000000016CrossRefPubMed

49.

Mohanraj R, Brodie MJ (2006) Diagnosing refractory epilepsy: response to sequential treatment schedules. Eur J Neurol 13(3):277–282. doi:10.1111/j.1468-1331.2006.01215.xCrossRefPubMed

50.

Devinsky O, Marsh E, Friedman D (2016) Cannabidiol in patients with treatment-resistant epilepsy - Authors’ reply. Lancet neurology 15(6):545–546. doi:10.1016/S1474-4422(16)00120-4CrossRefPubMed

51.

Devinsky O, Marsh E, Friedman D, Thiele E, Laux L, Sullivan J, Miller I, Flamini R, Wilfong A, Filloux F, Wong M, Tilton N, Bruno P, Bluvstein J, Hedlund J, Kamens R, Maclean J, Nangia S, Singhal NS, Wilson CA, Patel A, Cilio MR (2016) Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial. Lancet neurology 15(3):270–278. doi:10.1016/S1474-4422(15)00379-8CrossRefPubMed

52.

Gloss D, Vickrey B (2014) Cannabinoids for epilepsy. Cochrane Database Syst Rev (3):CD009270. doi:10.1002/14651858.CD009270.pub3

53.

Mechoulam R, Carlini EA (1978) Toward drugs derived from cannabis. Die Naturwissenschaften 65 (4):174–179CrossRefPubMed

54.

Cunha JM, Carlini EA, Pereira AE, Ramos OL, Pimentel C, Gagliardi R, Sanvito WL, Lander N, Mechoulam R (1980) Chronic administration of cannabidiol to healthy volunteers and epileptic patients. Pharmacology 21(3):175–185CrossRefPubMed

55.

Rosenberg EC, Tsien RW, Whalley BJ, Devinsky O (2015) Cannabinoids and Epilepsy. Neurotherapeutics: the journal of the American Society for Experimental NeuroTherapeutics 12(4):747–768. doi:10.1007/s13311-015-0375-5

56.

Tzadok M, Uliel-Siboni S, Linder I, Kramer U, Epstein O, Menascu S, Nissenkorn A, Yosef OB, Hyman E, Granot D, Dor M, Lerman-Sagie T, Ben-Zeev B (2016) CBD-enriched medical cannabis for intractable pediatric epilepsy: The current Israeli experience. Seizure 35:41–44. doi:10.1016/j.seizure.2016.01.004CrossRefPubMed

57.

Krishnan S, Cairns R, Howard R (2009) Cannabinoids for the treatment of dementia. Cochrane Database Syst Rev (2):CD007204. doi:10.1002/14651858.CD007204.pub2

58.

van den Elsen GA, Ahmed AI, Lammers M, Kramers C, Verkes RJ, van der Marck MA, Rikkert MG (2014) Efficacy and safety of medical cannabinoids in older subjects: a systematic review. Ageing research reviews 14:56–64. doi:10.1016/j.arr.2014.01.007CrossRefPubMed

59.

Wallace MS, Marcotte TD, Umlauf A, Gouaux B, Atkinson JH (2015) Efficacy of Inhaled Cannabis on Painful Diabetic Neuropathy. J Pain 16(7):616–627. doi:10.1016/j.jpain.2015.03.008CrossRefPubMedPubMedCentral

60.

Behrendt S, Wittchen HU, Hofler M, Lieb R, Beesdo K (2009) Transitions from first substance use to substance use disorders in adolescence: is early onset associated with a rapid escalation? Drug and alcohol dependence 99(1-3):68–78. doi:{rs 10.1016/j.drugalcdep.2008.06.014 DOI}}CrossRefPubMed

61.

61. -Europäischen_Union AfVd (2015) Europäischer Drogenbericht 2015. In: Drogensucht EBfDu (ed)

62.

Drogenbeauftragte_der_Bundesregierung (2016) Drogen- und Suchtbericht 2016 vorgestellt: Mehr Achtsamkeit für unsere Gesundheit schaffen! http://www.drogenbeauftragte.de/presse/pressekontakt-und-mitteilungen/2016/2016-2-quatarl/drogen-und-suchtbericht-2016-vorgestellt-mehr-achtsamkeit-fuer-unsere-gesundheit-schaffen.html. Accessed 25.07.2017 2017

63.

Large M, Sharma S, Compton MT, Slade T, Nielssen O (2011) Cannabis use and earlier onset of psychosis: a systematic meta-analysis. Archives of general psychiatry 68(6):555–561. doi:10.1001/archgenpsychiatry.2011.5CrossRefPubMed

64.

Marconi A, Di Forti M, Lewis CM, Murray RM, Vassos E (2016) Meta-analysis of the Association Between the Level of Cannabis Use and Risk of Psychosis. Schizophrenia bulletin 42(5):1262–1269. doi:10.1093/schbul/sbw003CrossRefPubMedPubMedCentral

65.

Moore TH, Zammit S, Lingford-Hughes A, Barnes TR, Jones PB, Burke M, Lewis G (2007) Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet 370(9584):319–328. doi:10.1016/S0140-6736(07)61162-3CrossRefPubMed

66.

Myles N, Newall H, Nielssen O, Large M (2012) The association between cannabis use and earlier age at onset of schizophrenia and other psychoses: meta-analysis of possible confounding factors. Current pharmaceutical design 18(32):5055–5069CrossRefPubMed

67.

van der Meer FJ, Velthorst E, Meijer CJ, Machielsen MW, de Haan L (2012) Cannabis use in patients at clinical high risk of psychosis: impact on prodromal symptoms and transition to psychosis. Current pharmaceutical design 18(32):5036–5044CrossRefPubMed

68.

Kirkbride JB, Errazuriz A, Croudace TJ, Morgan C, Jackson D, Boydell J, Murray RM, Jones PB (2012) Incidence of schizophrenia and other psychoses in England, 1950-2009: a systematic review and meta-analyses. PloS one 7(3):e31660. doi:10.1371/journal.pone.0031660CrossRefPubMedPubMedCentral

69.

Lev-Ran S, Le Foll B, McKenzie K, George TP, Rehm J (2013) Bipolar disorder and co-occurring cannabis use disorders: characteristics, co-morbidities and clinical correlates. Psychiatry research 209(3):459–465. doi:10.1016/j.psychres.2012.12.014CrossRefPubMed

70.

Silins E, Fergusson DM, Patton GC, Horwood LJ, Olsson CA, Hutchinson DM, Degenhardt L, Tait RJ, Borschmann R, Coffey C, Toumbourou JW, Najman JM, Mattick RP, Cannabis Cohorts Research C (2015) Adolescent substance use and educational attainment: An integrative data analysis comparing cannabis and alcohol from three Australasian cohorts. Drug and alcohol dependence 156:90–96. doi:10.1016/j.drugalcdep.2015.08.034CrossRefPubMed

71.

Gentes EL, Schry AR, Hicks TA, Clancy CP, Collie CF, Kirby AC, Dennis MF, Hertzberg MA, Beckham JC, Calhoun PS (2016) Prevalence and correlates of cannabis use in an outpatient VA posttraumatic stress disorder clinic. Psychology of addictive behaviors: journal of the Society of Psychologists in Addictive Behaviors 30(3):415–421. doi:10.1037/adb0000154CrossRef

72.

Manhapra A, Stefanovics E, Rosenheck R (2015) Treatment outcomes for veterans with PTSD and substance use: Impact of specific substances and achievement of abstinence. Drug and alcohol dependence 156:70–77. doi:10.1016/j.drugalcdep.2015.08.036CrossRefPubMedPubMedCentral

73.

Wilkinson ST, Stefanovics E, Rosenheck RA (2015) Marijuana use is associated with worse outcomes in symptom severity and violent behavior in patients with posttraumatic stress disorder. The Journal of clinical psychiatry 76(9):1174–1180. doi:10.4088/JCP.14m09475CrossRefPubMed

74.

Johnson MJ, Pierce JD, Mavandadi S, Klaus J, Defelice D, Ingram E, Oslin DW (2016) Mental health symptom severity in cannabis using and non-using Veterans with probable PTSD. Journal of affective disorders 190:439–442. doi:10.1016/j.jad.2015.10.048CrossRefPubMed

75.

Medizinischer_Dienst_des_Spitzenverbandes_Bund_der_Krankenkassen (2017) Fragen und Antworten zur neuen Regelung zu Cannabinoiden in der GKV. MDS e.V. MDS e.V., Essen

76.

§ 24 a 0,5 Promillegrenze (2014). STVG Straßenverkehrsgesetz.

Titel: GKV-Verordnung von Cannabis — Teil 2: Anwendungspraxis
Bei Cannabis auf BTM-Rezept Haftungs- und Regressrisiko beachten
verfasst von: Prof. Dr. med. Wolfgang Freund
Ludwig Laub
Prof. Dr. med. Ulrich W. Preuss
Publikationsdatum: 11.11.2017
Verlag: Springer Medizin
Erschienen in: NeuroTransmitter / Ausgabe 11/2017
Print ISSN: 1436-123X
Elektronische ISSN: 2196-6397
DOI: https://doi.org/10.1007/s15016-017-6196-5

Neu in den Fachgebieten Neurologie und Psychiatrie

18.04.2024 | Arterielle Hypertonie | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Bei Cannabis auf BTM-Rezept Haftungs- und Regressrisiko beachten

Zusammenfassung

Das könnte Sie auch interessieren

Wirkt Cannabis bei neurologischen oder psychiatrischen Indikationen?

Neu in den Fachgebieten Neurologie und Psychiatrie

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

Delir kann Demenz begünstigen

Manche Gestagene können das Risiko für Meningeome erhöhen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 11/2017

CME: Wie kognitive Veränderungen im Alter die Fahreignung beeinflussen

Was bei der Verordnung von Cannabis zulasten der GKV zu beachten ist

Umfassende Betrachtung der ZNS-Erkrankungen statt Spezialistentum

Zukunft trifft Alltag in Klinik und Praxis

Sondergutachten empfiehlt Übergang zu Krankheitsvollmodell

Morbus Parkinson: Wirksamkeit der Therapie optimieren

Das könnte Sie auch interessieren

Wirkt Cannabis bei neurologischen oder psychiatrischen Indikationen?

Neu in den Fachgebieten Neurologie und Psychiatrie

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

Delir kann Demenz begünstigen

Manche Gestagene können das Risiko für Meningeome erhöhen